ReviewFrontiers in oncology2022
Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial.Nature communications · 2025Trial
- Current status and challenges of immune checkpoint inhibitors in liver cancer: from monotherapy to combination strategies.Medical oncology (Northwood, London, England) · 2026Review
- Targeting SMYD2 improves immunotherapy response in experimental hepatocellular carcinoma.Molecular therapy. Oncology · 2026Article
- Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances.Clinical and experimental medicine · 2026Review
- <p>Converting 'cold' to 'hot' hepatocellular carcinoma for improved immunotherapy (Review)</p>.Molecular medicine reports · 2026Review
- Current and Future Landscape of Hepatocellular Carcinoma Treatment.Oncology research · 2026Review
- The Transcriptional Role of Circular RNAs in Drug Resistance by Modulating the miRNA/mRNA Axis.Experientia supplementum (2012) · 2026Article
- Drug resistance mechanisms of immunotherapy and translational strategies for reversing resistance for hepatocellular carcinoma: from bench to bedside.Frontiers in immunology · 2026Review
- Targeting the TIGIT/CD155-induced metabolic checkpoint in NK cells restores anti-tumor immunity and suppresses hepatocellular carcinoma growth.Frontiers in immunology · 2026Article
- Albiflorin enhances the antitumor effects of propofol in hepatocellular carcinoma cells by inhibiting the Wnt/β-catenin signaling activation.Translational cancer research · 2025Article
- Article
- Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges.World journal of transplantation · 2025Review
- Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models.Gut and liver · 2025Review
- LINC00870 promotes imatinib resistance in gastrointestinal stromal tumor via inhibiting PIGR glycosylation modifications.Heliyon · 2025Article
- Assessing the Causal Effect of Circulating Protein-To-Protein Ratio on the Risk of Morbidity of Hepatocellular Carcinoma.Cancer medicine · 2025Article
- Frontiers in thoracic oncology: new breakthroughs in molecular targets and immunotherapy.Frontiers in immunology · 2025Review
- Comparative analysis of PD-L1 expression and tumor-infiltrating lymphocytes between primary breast cancer and matched metastatic lesions: implications for immunotherapy.Central-European journal of immunology · 2025Article
- Dexmedetomidine inhibits the Wnt/β-catenin pathway, regulates ferroptosis in bladder cancer cells and the tumor immune microenvironment, and suppresses tumorigenesis in a mouse bladder cancer model.Central-European journal of immunology · 2025Article
- The impact of ferroptosis and ferroptosis-related non-coding RNAs on breast cancer progression.Frontiers in cell and developmental biology · 2024Review
- Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of hepatocellular carcinoma over the past few years. However, only a limited proportion of patients with hepatocellular carcinoma respond to immunotherapy. Despite the significant breakthroughs, the molecular mechanisms that drive immune responses and evasion are largely unresolved. Predicting tumor response and resistance to immune checkpoint inhibitors is a significant challenge. In this review, we focus on the current research progress of immune checkpoint inhibitors in hepatocellular carcinoma. Importantly, this review highlights the underlying mechanisms of resistance to immune checkpoint inhibitors and summarizes potential strategies to overcome the resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.